CA2442366A1 - Inhibiteurs de l'histone deacetylase - Google Patents

Inhibiteurs de l'histone deacetylase Download PDF

Info

Publication number
CA2442366A1
CA2442366A1 CA002442366A CA2442366A CA2442366A1 CA 2442366 A1 CA2442366 A1 CA 2442366A1 CA 002442366 A CA002442366 A CA 002442366A CA 2442366 A CA2442366 A CA 2442366A CA 2442366 A1 CA2442366 A1 CA 2442366A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
alkoxy
hydroxyl
hydrocarbon chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002442366A
Other languages
English (en)
Other versions
CA2442366C (fr
Inventor
Hsuan-Yin Lan-Hargest
Robert J Kaufman
Norbert L. Wiech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Errant Gene Therapeutics LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/812,945 external-priority patent/US7312247B2/en
Priority claimed from US09/812,944 external-priority patent/US6495719B2/en
Priority claimed from US10/025,947 external-priority patent/US8026280B2/en
Application filed by Individual filed Critical Individual
Priority to CA2783647A priority Critical patent/CA2783647A1/fr
Publication of CA2442366A1 publication Critical patent/CA2442366A1/fr
Application granted granted Critical
Publication of CA2442366C publication Critical patent/CA2442366C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2442366A 2001-03-27 2002-03-25 Inhibiteurs de l'histone deacetylase Expired - Fee Related CA2442366C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2783647A CA2783647A1 (fr) 2001-03-27 2002-03-25 Inhibiteurs de l'histone deacetylase

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US81294001A 2001-03-27 2001-03-27
US09/812,944 2001-03-27
US09/812,940 2001-03-27
US09/812,945 US7312247B2 (en) 2001-03-27 2001-03-27 Histone deacetylase inhibitors
US09/812,944 US6495719B2 (en) 2001-03-27 2001-03-27 Histone deacetylase inhibitors
US09/812,945 2001-03-27
US10/025,947 US8026280B2 (en) 2001-03-27 2001-12-26 Histone deacetylase inhibitors
US10/025,947 2001-12-26
PCT/US2002/008836 WO2002076941A2 (fr) 2001-03-27 2002-03-25 Inhibiteurs de l'histone deacetylase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2783647A Division CA2783647A1 (fr) 2001-03-27 2002-03-25 Inhibiteurs de l'histone deacetylase

Publications (2)

Publication Number Publication Date
CA2442366A1 true CA2442366A1 (fr) 2002-10-03
CA2442366C CA2442366C (fr) 2012-09-25

Family

ID=27487458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2442366A Expired - Fee Related CA2442366C (fr) 2001-03-27 2002-03-25 Inhibiteurs de l'histone deacetylase

Country Status (4)

Country Link
EP (1) EP1408946A4 (fr)
AU (1) AU2002250401A1 (fr)
CA (1) CA2442366C (fr)
WO (1) WO2002076941A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1291015A1 (fr) 2001-09-10 2003-03-12 Lunamed AG Compositions à libération prolongée d'un agent actif
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
EP1567142A4 (fr) * 2002-11-20 2005-12-14 Errant Gene Therapeutics Llc Traitement de cellules pulmonaires avec des inhibiteurs d'histone deacetylase
US7652036B2 (en) 2003-02-25 2010-01-26 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
AR050552A1 (es) * 2004-09-02 2006-11-01 Osi Pharm Inc Mercaptoamidas como inhibidores de histona desacetilasa
WO2006029818A2 (fr) * 2004-09-16 2006-03-23 Dsm Ip Assets B.V. Nouvelles compositions cosmetiques
CA2615105A1 (fr) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Inhibiteurs de l'histone deacetylase
GB0620823D0 (en) 2006-10-19 2006-11-29 Univ London Histone deacetylase inhibitors
JP2019189648A (ja) * 2019-07-08 2019-10-31 国立大学法人東京農工大学 シス桂皮酸類縁体、重力屈性調節剤
CN110523541B (zh) * 2019-09-04 2021-09-28 中南大学 一种烷基硫醚基乙基羟肟酸药剂及其制备方法与应用
CN114805235B (zh) * 2022-05-09 2024-04-23 江苏中旗科技股份有限公司 一种多取代异恶唑烷酮及其中间体的合成制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886278A (en) * 1973-08-22 1975-05-27 Mead Johnson & Co Ammonium carboxylate sebum inhibition process
JPS6054339A (ja) * 1983-09-05 1985-03-28 Kuraray Co Ltd 不飽和カルボン酸エステルの製造方法
JP3065636B2 (ja) * 1989-06-29 2000-07-17 塩野義製薬株式会社 ［ジ―ｔｅｒｔ―ブチル（ヒドロキシ）フェニルチオ］置換ヒドロキサム酸誘導体
GB9614366D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US6110955A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US6147224A (en) * 1998-10-01 2000-11-14 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors

Also Published As

Publication number Publication date
WO2002076941A3 (fr) 2004-02-12
AU2002250401A1 (en) 2002-10-08
EP1408946A4 (fr) 2004-06-09
WO2002076941A2 (fr) 2002-10-03
EP1408946A2 (fr) 2004-04-21
CA2442366C (fr) 2012-09-25

Similar Documents

Publication Publication Date Title
CA2442366A1 (fr) Inhibiteurs de l'histone deacetylase
CA2486402A1 (fr) Inhibiteurs d'histone desacetylase bases sur des composes alpha-chalcogenmethylcarbonyle
CA2486303A1 (fr) Inhibiteurs d'histone desacetylase bases sur des composes alpha-ceto-epoxydes
BR112019025748A8 (pt) Método para inibir o crescimento de cristal de roflumilast ou mudanças no tamanho de partícula em uma composição, composição farmacêutica e método de inibição de fosfodiesterase 4 em um paciente
ES2558127T3 (es) Composición cicatrizante para aplicación tópica
RU2013121788A (ru) Ингибиторы репликации вич
WO2001081312A3 (fr) Methode de traitement se basant sur l'utilisation de derives de phenyle et de biaryle comme inhibiteurs de prostaglandine e
CA2569155A1 (fr) Formulations contenant un casaicinoide, un anesthesiant local et/ou un agent antipruritique pour le traitement de la douleur
SK17392001A3 (sk) Použitie zlúčenín ako antibakteriálnych činidiel
JP2003505422A5 (fr)
NO20051426L (no) Behandling av melanom ved reduksjon i clusterin-nivaer
CA2670103A1 (fr) Inhibiteurs de la replication du vih
WO2014153238A2 (fr) Compositions, procédés et dispositifs destinés à favoriser la cicatrisation de plaie et à réduire les infections
WO2009015485A8 (fr) Inhibiteurs cycliques de la carnitine palmitoyltransférase et traitement anticancéreux
WO2009016629A3 (fr) Composition pharmaceutique et procédés apparentés
CO5180578A1 (es) Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas
MX2022009967A (es) Compuestos para el tratamiento de la infeccion por coronavirus.
TR200200410T2 (tr) Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri.
RU2013131014A (ru) Композиции по уходу за полостью рта, содержащие хинон и дополнительный антимикробный агент
AU2558300A (en) Substituted stilbene compounds with vascular damaging activity
Ghangurde et al. Role of chemically modified tetracyclines in the management of periodontal diseases: a review
ES2369854T3 (es) Sales de calcio para el tratamiento de la psoriasis, la dermatitis y la caspa.
KR950702554A (ko) 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents)
CA2563659A1 (fr) Procede de traitement des problemes des yeux secs et de l'uveite
AR047708A1 (es) Moduladores de oxidecahidronaftaleno de hm74

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180326